1 min read
Symphogen A/S Licenses the Selexis SUREtechnology Expression Platform and Cell Line
Geneva, Switzerland, December 9, 2014 – Selexis SA, a serial innovation company with proven technologies for biologic...
Geneva, Switzerland, December 9, 2014 – Selexis SA, a serial innovation company with proven technologies for biologic...
Data addresses key issues associated with effective translation, translocation and secretion of therapeutic proteins in...
Preliminary Data from the Successful Proof-of-Concept Program Published in the June Issue of BioProcess International
...
Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Mammalian Cell Line Development...
Dr. Igor Fisch to Present Data on Using Genome Engineering and the Selexis SURE CHO-Mplus Libraries for Optimal...
Company CSO to Present Data on the Selexis SURE CHO-Mplus™ Libraries
Geneva, Switzerland, April 23 2013 – Selexis SA, a...
Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced Production of Monoclonal...
A Webinar Hosted by Selexis SA
Selexis CSO Demonstrates How the Selexis SURE CHO-Mplus™ Libraries Can Dramatically...
Selexis to Meet with Biopharmaceutical Companies Interested in Protein Drug Discovery, Cell Line Development and Lead...
Expansion to Include the Selexis SURE CHO-M Cell Line™
Geneva, Switzerland (PRNEWSWIRE) February 20, 2013 – Selexis SA,...
Geneva, Switzerland, January 13, 2014 – Selexis SA, a serial innovation company focused on drug discovery for lead...
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.